WO2010027150A2 - New preparation of hydroxychloroquine - Google Patents

New preparation of hydroxychloroquine Download PDF

Info

Publication number
WO2010027150A2
WO2010027150A2 PCT/KR2009/004660 KR2009004660W WO2010027150A2 WO 2010027150 A2 WO2010027150 A2 WO 2010027150A2 KR 2009004660 W KR2009004660 W KR 2009004660W WO 2010027150 A2 WO2010027150 A2 WO 2010027150A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxychloroquine
pressure
bars
reaction
dichloroquinoline
Prior art date
Application number
PCT/KR2009/004660
Other languages
French (fr)
Other versions
WO2010027150A3 (en
Inventor
Yun Sik Min
Hyun-Sung Cho
Kil Woong Mo
Original Assignee
Dae He Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020080088070A priority Critical patent/KR101115412B1/en
Priority to KR10-2008-0088070 priority
Application filed by Dae He Chemical Co., Ltd. filed Critical Dae He Chemical Co., Ltd.
Publication of WO2010027150A2 publication Critical patent/WO2010027150A2/en
Publication of WO2010027150A3 publication Critical patent/WO2010027150A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/46Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Abstract

The present invention provides a process for the preparation of hydroxychloroquine by the reaction of 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine under high pressure.

Description

NEW PREPARATION OF HYDROXYCHLOROQUINE
The present invention relates to a process for the preparation of hydroxychloroquine which is therapeutically effective as an anti-malarial drug.
Hydroxychloroquine, which is 2-[[4-[7-chloro-4-quinolinyl]amino]pentyl]-ethylamino]ethanol and has a structure of the following formula (1), was first disclosed in US Patent No. 2,546,658. This US patent teaches a process for preparing hydroxychloroquine diphosphate, which involves reacting 4,7-dichloroquinoline of the following formula 2 with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine of the following formula 3 in the presence of potassium iodide (KI) and phenol at a temperature of 125 to 130℃ for 18 hours or more to thereby prepare crude hydroxychloroquine to which diphosphate is then attached to obtain hydroxychloroquine diphosphate with a yield of 35% (see Reaction Scheme 1 below).
[Reaction Scheme 1]
Figure PCTKR2009004660-appb-I000001
US Patent No. 5,314,894 discloses a process for preparing (S)-(+)-hydroxychloroquine wherein 4,7-dichloroquinoline and (S)-N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine with N,N-diisopropylethylamine (b.p 127℃ were heated at reflux for 48 hours to obtain (S)-(+)-hydroxychloroquine with a yield of 46%.
Further, CA Patent No. 2,561,987 teaches a process for preparing hydroxychloroquine, which involves reacting 4,7-dichloroquinoline (2) with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine (3) at a temperature of 120 to 130℃ for 20 to 24 hours, and introducing a protective group, as illustrated below, to the reaction product so as to facilitate the removal of impurities, followed by hydrolysis of the protective group to obtain a desired product hydroxychloroquine.
Figure PCTKR2009004660-appb-I000002
In formulae A, B, C, each PG represents a protective group.
However, with currently known methods of preparing hydroxychloroquine and its acid addition salts, there is a difficulty in elimination of undesirable byproducts upon the preparation of acid addition salts, due to using a toxic solvent such as phenol or a reagent such as N,N-diisopropylethylamine, which has a high boiling point and a structure similar to that of the final product. Particularly, a long reaction time at high temperatures may result in increased production costs and buildup of byproducts, for which a higher-efficiency synthesis method of hydroxychloroquine and disulfate is required in related industrial fields.
To this end, there is a need for the development of a novel method of synthesizing hydroxychloroquine, which is capable of overcoming a variety of problems and disadvantages as discussed above and is capable of providing a desired product with higher purity and yield.
The present invention is intended to provide a novel method for preparing hydroxychloroquine, which is capable of inhibiting the formation of byproducts and decreasing production costs by significantly decreasing a reaction temperature and a reaction time using a certain pressure, without a catalyst and a reaction solvent.
The present invention provides a novel method for preparing hydroxychloroquine using a pressure, which comprises reacting 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine under high pressure to obtain hydroxychloroquine of the formula:
Figure PCTKR2009004660-appb-I000003
That is, the method of the present invention provides the preparation of hydroxychloroquine by the reaction of 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine without use of a catalyst and a solvent.
As used herein, the term "high pressure" refers to a more greater pressure than atmospheric pressure(1 atm, about 1 bar), which is preferably in the range of 5 to 30 bars and more preferably 10 to 20 bars.
In the context of the present invention, the high pressure is exerted by an inert gas such as nitrogen (N2) or argon (Ar) gas or by moisture-free air.
The reaction time is preferably within 10 hours and more preferably 6 hours.
The reaction temperature is preferably in the range of 100 to 120℃, although it may vary.
A reaction molar ratio of 4,7-dichloroquinoline and N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine is preferably in the range of 1:1.05 to 1.5 and more preferably 1:1.05 to 1.1, although it may vary.
Further, the present invention provides a process for preparing hydroxychloroquine sulfate, comprising:
(a) reacting 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine under high pressure to obtain hydroxychloroquine of the formula:
Figure PCTKR2009004660-appb-I000004
; and
(b) reacting the hydroxychloroquine of Step (a) with sulfuric acid (H2SO4) to obtain hydroxychloroquine sulfate.
Here, reaction conditions for Step (a) are as defined above.
The preparation process of hydroxychloroquine according to the present invention will be described in greater detail hereinafter.
The process is carried out as follows. First, 4,7-dichloroquinoline and N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine in a molar ratio of 1:1.1 were placed into a high pressure reactor. Internal pressure of the reactor is then adjusted to the range of 5 to 20 bars and preferably 10 to 15 bars by nitrogen pressure. The reactor is stirred at 80℃ for 30 min until 4,7-dichloroquinoline is completely dissolved, followed by further stirring at a temperature of 100 to 120℃ for 4 to 6 hours.
The present invention enables the production of hydroxychloroquine with high purity and high yield while providing various advantages in that the formation of byproducts is inhibited by decreasing a reaction temperature and significantly decreasing a reaction time using a pressure without use of a catalyst and a reaction solvent, and production costs are reduced.
Now, the present invention will be described in more detail with reference to the following Examples. These examples are provided only for illustrating the present invention and should not be construed as limiting the scope and spirit of the present invention.
Reagents used in following examples are directly available from Dae He Chemical Co., Ltd. (Korea) or otherwise is purchased from Aldrich. All solvents are commercially available from Samsung Fine Chemical Co., Ltd. (Korea).
Example 1: Preparation of hydroxychloroquine using pressure of 20 bars
10 kg of 4,7-dichloroquinoline and 11.4 kg (1.0 eq) of N'-ethyl-N'-β -hydroxyethyl-1,4-pentadiamine were introduced into a high pressure reactor which was then filled with nitrogen gas to a pressure of 20 bars and stirred at 80℃ for 30 min, followed by further stirring at 100 to 110℃ for 4 hours. The reactor was cooled to a temperature of about 70 to 80℃. And then 30 kg of a 3N HCl aqueous solution and 20 kg of chloroform were added thereto, and the mixture was cooled to room temperature, stirred for 1 hour, and allowed to stand such that a desired product was transferred to the aqueous layer while the remaining byproducts were transferred to the chloroform layer(This procedure was repeated three times). The aqueous layer containing a desired compound was collected. The thus-collected aqueous layer was extracted again with 40 kg of a 2N NaOH aqueous solution and chloroform to remove the aqueous layer, and 5 kg of activated carbon and 5 kg of alumina was added thereto, followed by stirring at 40℃ for 6 hours and filtration. The filtrate was concentrated under reduced pressure and 60 kg of ethylene dichloride (EDC) was added thereto to result in crystallization. The resulting residue was were filtered and dried under vacuum at 40℃ to afford 14 kg (yield: 78.2%) of the title compound.
1H NMR (500 MHz): δ(CDCl3) 7.47(d), 7.92(d), 7.72(d), 7.33(dd), 6.38(d), 5.09(d), 3.50-3.80(m), 2.40-2.70(m), 1.50-1.80(m), 1.30(d), 1.00(t)
Example 2: Preparation of hydroxychloroquine (formula 1) using pressure of 10 bars
10 kg of 4,7-dichloroquinoline and 11.4 kg (1.0 eq) of N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine were introduced into a high pressure reactor which was then filled with nitrogen gas to a pressure of 10 bars, and stirred at 80℃ for 30 min, followed by further stirring at 100 to 110℃ for 6 hours. The reactor was cooled to a temperature of about 70 to 80℃. And then 30 kg of a 3N HCl aqueous solution and 20 kg of chloroform were added thereto, and the mixture was cooled to room temperature, stirred, and allowed to stand such that a desired product was transferred to the aqueous layer while the remaining byproducts were transferred to the chloroform layer(This procedure was repeated three times). The aqueous layer containing a desired compound was collected. The thus-collected aqueous layer was extracted again with 40 kg of a 2N NaOH aqueous solution and 20 kg of chloroform to remove the aqueous layer, and 5 kg of activated carbon and 5 kg of alumina was added thereto, followed by stirring at 40℃ for 6 hours and filtration. The filtrate was concentrated under reduced pressure and 60 kg of EDC was added thereto to result in crystallization. The resulting residue was filtered and dried under vacuum at 40℃ to afford 14.5 g (yield: 75.5%) of the title compound.
1H NMR (500 MHz) values of the obtained compound were identical with those as in Example 1.
Example 3: Preparation of hydroxychloroquine sulfate
10 kg of hydroxychloroquine prepared in Example 1 was dissolved in 100 kg of ethanol, and the solution was cooled to 10℃. A solution of concentrated sulfuric acid (1.58 kg, 1.0 eq) in 50 kg of ethanol was slowly added thereto with stirring for 12 hours. The reaction solution was filtered to afford 11.0 kg (85.2%) of the title compound as a white material.
1H NMR (300 MHz): δ(D2O) 8.08(d), 7.95(d), 7.53(d), 7.35(dd) 6.64(d), 3.94(d), 3.60-3.70(m), 2.90-3.30(m), 1.50-1.80(m), 1.23(d), 1.09(t)
Example 4: Preparation of hydroxychloroquine sulfate
10 kg of hydroxychloroquine prepared in Example 1 was dissolved in 100 kg of ethyl acetate, and a solution of concentrated sulfuric acid (1.58 kg, 1.0 eq) in 50 kg of ethyl acetate was slowly added thereto with stirring at 30℃. Thereafter, the reaction solution was stirred at 0℃ for 12 hours and filtered to afford 10.0 kg (77.5%) of the title compound as a white material.
1H NMR (500 MHz) values of the obtained compound were identical with those as in Example 3.

Claims (11)

  1. A process for preparing hydroxychloroquine, comprising reacting 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine under high pressure to obtain hydroxychloroquine of the formula:
    Figure PCTKR2009004660-appb-I000005
  2. The process according to claim 1, wherein the reaction is carried out in the absence of catalyst and solvent.
  3. The process according to claim 1, wherein the high pressure is 5 bars or higher.
  4. The process according to claim 3, wherein the high pressure is in the range of 10 to 20 bars.
  5. The process according to any one of claims 1 to 4, wherein the high pressure is applied by an inert gas such as nitrogen (N2) or argon (Ar) gas or by moisture-free air.
  6. The process according to any one of claims 1 to 4, wherein the reaction time is within 6 hours.
  7. The process according to any one of claims 1 to 4, wherein the reaction temperature is in the range of 100 to 120℃.
  8. A process for preparing hydroxychloroquine sulfate, comprising:
    (a) reacting 4,7-dichloroquinoline with N'-ethyl-N'-β-hydroxyethyl-1,4-pentadiamine under high pressure of nitrogen (N2) gas to obtain hydroxychloroquine of the formula:
    Figure PCTKR2009004660-appb-I000006
    ; and
    (b) reacting the hydroxychloroquine of Step (a) with sulfuric acid (H2SO4) to obtain hydroxychloroquine sulfate.
  9. The process according to claim 8, wherein the high pressure is 5 bars or higher.
  10. The process according to claim 9, wherein the high pressure is in the range of 10 to 20 bars.
  11. The process according to any one of claims 8 to 10, wherein the high pressure is applied by an inert gas such as nitrogen (N2) or argon (Ar) gas or by moisture-free air.
PCT/KR2009/004660 2008-09-08 2009-08-21 New preparation of hydroxychloroquine WO2010027150A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020080088070A KR101115412B1 (en) 2008-09-08 2008-09-08 New preparation of hydroxychloroquine
KR10-2008-0088070 2008-09-08

Publications (2)

Publication Number Publication Date
WO2010027150A2 true WO2010027150A2 (en) 2010-03-11
WO2010027150A3 WO2010027150A3 (en) 2010-06-17

Family

ID=41797613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004660 WO2010027150A2 (en) 2008-09-08 2009-08-21 New preparation of hydroxychloroquine

Country Status (2)

Country Link
KR (1) KR101115412B1 (en)
WO (1) WO2010027150A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102050781A (en) * 2010-12-21 2011-05-11 重庆康乐制药有限公司 Industrial preparation method of hydroxychloroquine sulfate
CN103724261A (en) * 2013-12-13 2014-04-16 武汉武药制药有限公司 Novel industrial production method for hydroxychloroquine sulfate
CN104230803A (en) * 2014-08-28 2014-12-24 重庆康乐制药有限公司 Preparation method of hydroxychloroquine sulfate
CN108727263A (en) * 2018-07-05 2018-11-02 上海中西三维药业有限公司 Hydroxychloroquine sulfate crystal form A and preparation method thereof
WO2019165337A1 (en) * 2018-02-26 2019-08-29 Virginia Commonwealth University High-yielding continuous flow synthesis of antimalarial drug hydroxychloroquine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5314894A (en) * 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561987A1 (en) * 2006-10-02 2008-04-02 Apotex Pharmachem Inc. Process for the preparation of highly pure hydroxychloroquine or a salt thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5314894A (en) * 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102050781A (en) * 2010-12-21 2011-05-11 重庆康乐制药有限公司 Industrial preparation method of hydroxychloroquine sulfate
CN103724261A (en) * 2013-12-13 2014-04-16 武汉武药制药有限公司 Novel industrial production method for hydroxychloroquine sulfate
CN104230803A (en) * 2014-08-28 2014-12-24 重庆康乐制药有限公司 Preparation method of hydroxychloroquine sulfate
WO2019165337A1 (en) * 2018-02-26 2019-08-29 Virginia Commonwealth University High-yielding continuous flow synthesis of antimalarial drug hydroxychloroquine
CN108727263A (en) * 2018-07-05 2018-11-02 上海中西三维药业有限公司 Hydroxychloroquine sulfate crystal form A and preparation method thereof

Also Published As

Publication number Publication date
WO2010027150A3 (en) 2010-06-17
KR20100029332A (en) 2010-03-17
KR101115412B1 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
RU2291861C2 (en) Method for preparing quinoline derivatives
CN1139596C (en) Crystalline amine salt of cefdinir
EP2951158B1 (en) Process for the preparation of ivacaftor and solvates thereof
CN101541818B (en) Process for preparation of 4'-azido cytidine derivatives
CN102985416B (en) Process of preparing a thrombin specific inhibitor
EP1339725B1 (en) Dna methyl transferase inhibitors
EP1712556B1 (en) Azithromycin monohydrate
KR20090090337A (en) Process for the synthesis of moxifloxacin hydrochloride
EP1274686B1 (en) Process for preparing 2-(4-chlorobenzolamino) -3- 2(1h) -quinolinon-4-yl proprionic acid
JP2005507900A (en) Citalopram manufacturing method
WO2008043996A2 (en) Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
EP2545063A2 (en) An improved process for the preparation of tenofovir disoproxil fumarate
EP2940001B1 (en) Method for producing purified form of amine compound
US8304531B2 (en) Process for the preparation of an (RP)-8-substituted cAMPS
WO2009134030A1 (en) Novel process for preparation of iopromide
KR100433436B1 (en) Method for the Synthesis of a Benzimidazole Compound
WO2014125506A2 (en) A process for the preparation of ivacaftor and its intermediates
US20060135777A1 (en) Method for the production of d-threo-2-phenyl-2-piperidine-2-yl acetates
WO2010030132A9 (en) Purification method for adefovir dipivoxil
ES2583375T3 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-D-ribofuranosyl nucleoside compounds
JP4892915B2 (en) Epalrestat manufacturing method
US20100267958A1 (en) Method for isolation and purification of montelukast
WO2007069049A2 (en) Processes for the preparation of pure zoledronic acid
KR20130091730A (en) Method for manufacturing of quinoline-3-carboxamides
EP2702034A2 (en) Preparation of fingolimod and its salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09811649

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09811649

Country of ref document: EP

Kind code of ref document: A2